Compare GKOS & TAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | TAP |
|---|---|---|
| Founded | 1998 | 1873 |
| Country | United States | United States |
| Employees | N/A | 16200 |
| Industry | Medical/Dental Instruments | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.5B |
| IPO Year | 2015 | N/A |
| Metric | GKOS | TAP |
|---|---|---|
| Price | $153.58 | $40.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 17 |
| Target Price | ★ $126.92 | $48.94 |
| AVG Volume (30 Days) | 692.4K | ★ 2.9M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $0.85 |
| Revenue Next Year | $27.43 | $0.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $38.04 |
| 52 Week High | $161.53 | $54.82 |
| Indicator | GKOS | TAP |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 53.50 |
| Support Level | $96.44 | $40.79 |
| Resistance Level | $161.53 | $42.65 |
| Average True Range (ATR) | 5.46 | 1.27 |
| MACD | -0.85 | 0.17 |
| Stochastic Oscillator | 55.40 | 55.25 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume in the US, Canada, and the United Kingdom. Through licensing agreements, it also brews and distributes beer and nonbeer beverage categories under partner brands from Heineken, Anheuser-Busch InBev, Asahi, Fever-Tree, and Coca-Cola. North America remains its largest market, accounting for nearly 80% of total revenue.